At present, there are very mature production procedures and quality control standards for the preparation of engineered cells. However, most of these operations are conducted in open systems. The processes are complex and time-consuming, and require heavy workloads. They are also easy to cause contamination, and involve large individual differences. These problems cause great challenges to clinical approval and implementation of engineered cells in terms of safety and quality consistency.Faced with complex samples from different tumor patients, achieving high-efficiency, standardized, and large-scale production and preparation, and finding methods or solutions to improve the process to meet the expected commercialization needs are the common concerns of smart cell manufacturers. The ultimate goal of all smart cell manufacturers is to improve production efficiency and product quality by creating centralized, specialized and refined smart devices, improving the quality of smart devices, and achieving refined and professional management while reduce costs.